KRAS and acute myeloid leukemia: K-RAS mutation occurs to a lower but still significant frequence in pediatric AML.11 NRAS is the most prominent; reported in 11%–30% of patients.12 All homologs were exclusively in codons 12, 13, and 61 conferring constitutive activation of the RAS protein, which is subsequently held in the GTP bound status leading to an increased activity of the RAS pathway causing an increased proliferation and a decreased apoptosis rate.13 RAS mutations were described in the various solid tumors as well as in hematologic malignancies.